Pharmaceutical Technology

JULY 7, 2025

Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated.

Labelling 52

Labelling Packaging Communication Hospitals 52

Pharmaceutical Technology

JULY 4, 2025

Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with chemotherapy drugs gemcitabine and cisplatin as neoadjuvant treatment, and as a monotherapy after bladder removal surgery. Imfinzi is a major revenue driver for AstraZeneca, generating around $4.7bn in sales in 2024.

Chemotherapy 52

Chemotherapy Packaging Labelling Communication 52

Pharmaceutical Technology

JULY 8, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Efbemalenograstim Alfa La in Chemotherapy Indu. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports LOA and PTSR Model - Efbemalenograstim Alfa La in Chemotherapy Indu. Find out more Sign up for our daily news round-up!

Packaging 52

Packaging Chemotherapy Hospitals Communication 52